Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Option Care Health Inc Market Cap
The Option Care Health Inc (OPCH) share price is expected to increase by 26.73% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered OPCH. Price targets range from $43.00 at the low end to $43.00 at the high end. The current analyst consensus for OPCH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Option Care Health Inc has a total of 1 Wall St Analyst ratings. There are 1 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Option Care Health Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| michael petusky Barrington | Buy | $35.0 | maintained | Jan 31, 2024 |
| joanna gajuk Bank of America Securities | Buy | $43.0 | maintained | Jan 3, 2024 |
| pito chickering Deutsche Bank | Buy | $35.0 | maintained | Oct 26, 2023 |
| lisa gill J.P. Morgan | Buy | $42.0 | maintained | Oct 25, 2023 |
| kevin fischbeck Bank of America Securities | Buy | $43.0 | maintained | Sep 5, 2023 |
| jamie perse Goldman Sachs | Buy | $41.0 | initiatedcoverage | Aug 9, 2023 |
| david s macdonald Truist Financial | Buy | $41.0 | maintained | Jul 28, 2023 |
| brian tanquilut Jefferies | Buy | $38.0 | initiatedcoverage | Feb 27, 2023 |
| brooks o'neil Lake Street | Buy | $45.0 | maintained | Jul 28, 2022 |
| richard close Canaccord Genuity | Buy | $24.0 | maintained | Aug 4, 2021 |
| gary taylor Cowen & Co. | Buy | $21.0 | initiatedcoverage | Jan 11, 2021 |
| matt larew William Blair | Buy | None | initiatedcoverage | Jan 6, 2020 |
| kevin ellich Craig-Hallum | Buy | $20.0 | maintained | Nov 6, 2019 |
| dana hambly Stephens | Hold | $14.0 | downgraded | Mar 18, 2019 |
| william bonello Craig-Hallum | Buy | $7.0 | initiatedcoverage | Apr 9, 2015 |
| mitra ramgopal Sidoti | Hold | None | downgraded | Feb 27, 2014 |
| matt weight Feltl | Buy | $20.0 | reiterated | Jun 17, 2013 |
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
When did it IPO
0
Staff Count
5,597
Country
United States
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Mr. John C. Rademacher
Market Cap
$6.01B
In 2023, OPCH generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that OPCH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
ALGM-USD
$31.09
$28.72
QLYS-USD
$164.57
BPOP-USD
$83.48
NXST-USD
$173.77
LFUS-USD
$247.13
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
